Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2016

View Archived Issues

BB-HB-331 demonstrates robust and durable suppression of HBV in vivo

Fudan University discloses sphigomyelin synthase 2 inhibitors

Bayer Schering Pharma patents sGC activators/PDE5 inhibitors

CJ CheilJedang reports FFAR1 agonists for diabetes

Sichuan Haisco Pharmaceutical introduces antineoplastic compounds

Torrent Pharmaceuticals describes MAPK 14 inhibitors

Otsuka Pharmaceutical patents compounds for the treatment of tuberculosis

Immusoft acquires Discovery Genomics

Sound Pharmaceuticals collaborates on phase II study of SPI-1005 for bipolar disorder

Abbott and collaborators launch study to evaluate and diagnose traumatic brain injury

Deflazacort now available through expanded access program for DMD

Partial clinical hold lifted on Medivation's pidilizumab

p53 might be useful to distinguish Langerhans cell hyperplasia from Langerhans cell histiocytosis

Theravance successfully completes single-ascending-dose phase I trial of TD-0714

Alnylam begins phase I/II trial of ALN-GO1 for primary hyperoxaluria type 1

FDA clears in vitro test for identifying carbapenem resistance genes

Nemolizumab demonstrates efficacy in phase II atopic dermatitis trial

Targovax reports 1-year overall survival data on TG-01 in pancreatic cancer

Amal Therapeutics receives Swiss grant to test immunotherapy combination treatments

Interim data from Viamet's phase IIb trial of VT-1161 for recurrent vulvovaginal candidiasis

Evotec achieves preclinical milestone in alliance with Padlock Therapeutics

BAFF expression correlates with severity of mycosis fungoides

Scripps Florida receives funding for obesity and weight control research

SD-101 cream promotes wound healing in patients with epidermolysis bullosa

Genmab achieves new milestone in daratumumab collaboration with Janssen

New Australian trial studies cord blood to treat cerebral palsy

Combioxin initiates phase I study of CAL-02 in severe pneumonia

MEDI-551 receives orphan drug designation for neuromyelitis optica

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.